Translational Research in ROS1-Positive NSCLC: Are We Moving Out of the Six Blind Men and the Elephant Stage?

J Thorac Oncol. 2024 Apr;19(4):525-527. doi: 10.1016/j.jtho.2024.01.009.

Authors

Jii Bum Lee¹, Misako Nagasaka²

Affiliations

¹ Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea. Electronic address: joy88lee@yuhs.ac.
² Division of Hematology-Oncology, Department of Medicine, Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, California; Chao Family Comprehensive Cancer Center, Orange, California.

PMID: 38582542
DOI: 10.1016/j.jtho.2024.01.009

No abstract available

Keywords: Crizotinib; NSCLC; ROS1 fusion; Variants.

Publication types

Editorial

MeSH terms

Carcinoma, Non-Small-Cell Lung* / genetics
Humans
Lung Neoplasms* / genetics
Protein Kinase Inhibitors
Protein-Tyrosine Kinases / genetics
Proto-Oncogene Proteins
Translational Research, Biomedical

Substances

Protein-Tyrosine Kinases
Proto-Oncogene Proteins
Protein Kinase Inhibitors
ROS1 protein, human